Risk factor
Strong trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Established in 1992 and headquartered in Shenzhen, China, Shenzhen Kangtai Biological Products Co., Ltd. is dedicated to the research, development, manufacturing, and commercialization of a diverse array of human vaccines across the Chinese market. The company's extensive portfolio includes essential immunizations such as the SARS-COV-2 vaccine, recombinant hepatitis B vaccine, and various pneumococcal disease vaccines (including 13-valent conjugate and 23-valent polysaccharide types). Its offerings also encompass combined vaccines like diphtheria, tetanus, acellular pertussis, and haemophilus influenzae type b, in addition to specific haemophilus influenzae type b conjugate, measles and rubella live attenuated, rabies, and inactivated poliomyelitis vaccines. Internationally, the company has partnered with YTB and Yong Tai Berhad to develop and commercialize a Covid-19 inactivated vaccine specifically for Malaysia.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of 300601.SZ is 14.8 and suggests 8.91% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommen